Vascular biology of cancer chemotherapeutic drugs

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2019) Vascular biology of cancer chemotherapeutic drugs. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 259-268. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_24)

Full text not currently available from Enlighten.


Developments in anticancer chemotherapeutic drugs have improved the prognosis for patients with a number of malignancies. Anticancer drugs are associated with a range of cardiovascular toxicities, which can occur due to direct cardiotoxic effects and to overlap between cellular pathways involved in cancer cell growth and pathways required for healthy cell signalling. Cardiovascular complications related to anticancer chemotherapy drugs have increased in parallel with improved cancer survival and include hypertension, myocardial dysfunction, heart failure, myocardial ischaemia, and thromboembolism. Cardiovascular specialists and oncologists are now working more closely through an evolving discipline known as Cardiovascular-Oncology, with an aim to prevent, detect early, and promptly manage cardiovascular complications that can occur during and/or after treatment with anticancer chemotherapy drugs.

Item Type:Book Sections
Glasgow Author(s) Enlighten ID:Lang, Professor Ninian and Cameron, Dr Alan and Touyz, Professor Rhian
Authors: Cameron, A. C., Touyz, R. M., and Lang, N. N.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Published Online:03 August 2019

University Staff: Request a correction | Enlighten Editors: Update this record